[Progress of researches on the antiparasitic activity of antimicrobial peptide LL-37].
Lou. J J; He. X X
Key Findings
- LL-37 is the only human cathelicidin peptide and shows activity against various parasites in experimental models
- Current anti‑parasitic drugs face resistance problems, prompting interest in peptide‑based alternatives
- Research is still at the review stage; concrete dosing, safety, and delivery methods for humans are not established
Practical Outcomes
- At this point LL-37 is not a ready‑to‑use supplement or treatment for biohackers. It highlights a promising direction, but you’d need to wait for more detailed studies before trying it in any protocol.
Summary
LL-37 is a natural human peptide that scientists have found can kill or slow down parasites in lab studies, so it might someday become an alternative to traditional anti‑parasitic drugs, but there’s no clear recipe or dosage for everyday use yet.
Abstract
Parasitic diseases caused by protozoan and helminth infections are still widespread across the world, notably in tropical and subtropical areas, which threaten the children and adult health. Long-term use of anti-parasitic drugs may result in reduced drug susceptibility and even drug resistance. Antimicrobial peptides have been demonstrated to inhibit parasite growth and development, which has potential antiparasitic values. LL-37, the only human antimicrobial peptide in the cathelicidin family, has been widely investigated. This paper reviews the progress of researches on the antiparasitic activity of LL-37, and discusses the prospects of LL-37 in the research of parasites.
Study Information
pubmed
2024
2024-03-25T00:00:00.000Z
10.16250/j.32.1374.2023157